2. UroToday Home
  3. Video Lectures

mHSPC Videos

VA Study Examines Use of Combination Therapies for mHSPC and Outcomes in Patients - Martin Schoen & Bruce Montgomery
December 13, 2024
Details
Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice? "Presentation" - Michael Morris
November 15, 2024
Details
Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break? "Presentation" - Bertrand Tombal
November 15, 2024
Details
MMAI Score Prognostic for Overall Survival in Oligometastatic Castration-Sensitive Prostate Cancer - Phuoc Tran & Tim Showalter
November 5, 2024
Details
Highlights in Prostate Cancer Treatment Advances from ESMO 2024 - Ursula Vogl
November 5, 2024
Details
Metformin Study Reveals Weight Management Benefits for ADT Therapy - Silke Gillessen
October 30, 2024
Details
UpFrontPSMA Trial Results: Lutetium-177 PSMA-617 in Hormone-Sensitive Prostate Cancer, Journal Club - Phillip Koo & Zachary Klaassen
October 15, 2024
Details
STAMPEDE2 Trial Explores Combination Niraparib and Abiraterone in mHSPC - Sarah Howlett & Mahaz Kayani
October 15, 2024
Details
ARANOTE Trial Implications for Metastatic Prostate Cancer Management, Journal Club - Rashid Sayyid & Zachary Klaassen
October 12, 2024
Details
First-Line Combination Treatment with PARP and Androgen Receptor-Signaling Inhibitors in HRR-Deficient mCRPC: Applying Clinical Study Findings to Clinical Practice in the United States - Beyond the Abstract
October 9, 2024
Details
Advancing mHSPC Treatment Options: ARANOTE Trial Analysis - Neal Shore & Fred Saad
October 7, 2024
Details
Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard
October 1, 2024
Details
Accelerated 177Lu-PSMA-617 Protocol Tested in STAMPEDE2 - Minal Padden-Modi & Nicholas James
September 27, 2024
Details
Darolutamide Improves Outcomes for mHSPC Patients in ARANOTE Trial - Fred Saad
September 26, 2024
Details
STAMPEDE2 SABR Trial for Oligometastatic Prostate Cancer Treatment - Hoda Abdel-Aty
September 24, 2024
Details
UpFrontPSMA Trial: Lutetium-PSMA + Docetaxel in mHSPC - Arun Azad
September 23, 2024
Details
Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC - Marta Garcia de Herreros
September 20, 2024
Details
EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore
September 19, 2024
Details
ZZ-FIRST Trial Demonstrates High PSA Response with Combination Therapy - Joaquin Mateo
September 18, 2024
Details
ARANOTE Study: Transforming Metastatic Hormone Sensitive Prostate Cancer Treatment - Fred Saad
September 16, 2024
Details
PEACE-1 Trial Reveals Key Genomic Alterations Linked to Survival in Prostate Cancer Patients - Cédric Pobel
September 16, 2024
Details
2024 NCCN Prostate Cancer Guidelines: Updates in M1 CSPC Treatment - Rashid Sayyid & Zachary Klaassen
September 6, 2024
Details
Cardiovascular Risks of ARSIs in Prostate Cancer: Meta-Analysis Findings, Journal Club - Rashid Sayyid & Zachary Klaassen
August 23, 2024
Details
RADIOSA Trial: SBRT vs SBRT+ADT for Oligorecurrent Prostate Cancer - Giulia Marvaso
August 21, 2024
Details
IMPLEMENT Study: Addressing the Underutilization of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer - Stacy Loeb
June 18, 2024
Details
NCCN 2024 Prostate Cancer Guidelines Update: Relugolix Gains Prominence in Treating Metastatic Castration-Sensitive Prostate Cancer - Rashid Sayyid & Zachary Klaassen
June 15, 2024
Details
Enzalutamide Plus 5-Alpha Reductase Inhibitors for Castrate-Sensitive Prostate Cancer: A Phase 2 Trial - Deepak Kilari
June 13, 2024
Details
Prognostic Power of Multi-Modal Artificial Intelligence Biomarker in CHAARTED Trial Subset - Mark Markowski
June 12, 2024
Details
OASIS Project Highlights the Survival Benefits of Rapid PSA Decline with Apalutamide in Prostate Cancer - Benjamin Maughan
June 12, 2024
Details
Escalation Strategies for Suboptimal PSA Decline in mHSPC - Mary-Ellen Taplin
May 28, 2024
Details
Radiating the Primary Tumor in Metastatic Hormone-Sensitive Prostate Cancer - Sandy Srinivas
May 28, 2024
Details
Prognostic and Predictive Factors in Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith
May 24, 2024
Details
Sequencing Therapies in mCRPC After Progression on Combination Treatment - Ian Davis
May 24, 2024
Details
Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis
May 23, 2024
Details
Optimal Imaging Standards for Metastatic Castration-Sensitive Prostate Cancer - Michael Morris
May 23, 2024
Details
The EvoPAR-Prostate 01 Trial: Novel PARP Inhibitor Saruparib in mHSPC - Neeraj Agarwal
May 22, 2024
Details
Darolutamide Outcomes in European Patients with Metastatic Hormone-Sensitive Prostate Cancer from the ARASENS Trial - Bertrand Tombal
April 23, 2024
Details
Local Therapy in mHSPC: Who Does Really Benefit? - Alberto Bossi
April 23, 2024
Details
Maximizing Survival in Metastatic Hormone-Sensitive Prostate Cancer: The Role of Triplet Therapy - Kelvin Moses
April 15, 2024
Details
The Role of Urologists in Managing De Novo Metastatic Prostate Cancer - Benjamin Lowentritt
April 15, 2024
Details
Teamwork and Trust: Keys to Seamless Prostate Cancer Care Across Specialties - Paul Eber & Brad Somer
April 15, 2024
Details
Best Practices for Successfully Implementing Triplet Therapy in mHSPC - Christopher Pieczonka
April 12, 2024
Details
Treating Metastatic Hormone-Sensitive Prostate Cancer: Beyond Counting Metastases - Karim Fizazi
April 12, 2024
Details
Urology-Oncology Collaboration: Keys to Optimal Care in Metastatic Prostate Cancer - Damian Sorce & Manojkumar Bupathi
April 5, 2024
Details
Coordinating Complex Care in High-Volume mHSPC Through Multidisciplinary Communication - Jonathan Henderson & Sunil Kakadia
March 20, 2024
Details
Optimizing mHSPC Care and Collaboration for Triplet Therapy - Jason Hafron & Elisabeth Heath
March 13, 2024
Details
ARASENS Subgroup Analysis on Triplet Therapy Improves Outcomes for Black Patients with mHSPC, Journal Club - Rashid Sayyid & Zachary Klaassen
March 11, 2024
Details
Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans
March 1, 2024
Details
Adopting a Multidisciplinary Approach to Optimize Treatment Decisions for Patients with Metastatic Prostate Cancer - Michael Williams & Mark Fleming
March 1, 2024
Details
LIBERTAS Trial Tests Less Treatment, Better Quality of Life in Responding mHSPC Patients - Arun Azad
February 29, 2024
Details
Systematic Review Sheds Light on Treatment Intensification in Metastatic Prostate Cancer - Peter Goebell
February 22, 2024
Details
Analyzing mHSPC Patient Responses to ADT with Enzalutamide vs. Apalutamide - Benjamin Lowentritt
February 20, 2024
Details
Collaborating on Triplet Therapy for Metastatic Hormone-Sensitive Prostate Cancer - Daniel Saltzstein
February 5, 2024
Details
Building an Integrated, Multidisciplinary Team to Optimize Care for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Chandler Park & Ryan Malone
February 5, 2024
Details
Communication for Optimal Care in Patients Selected for Triplet Therapy Between Urology and Community Oncology - Vahan Kassabian & Sreekanth Reddy
January 29, 2024
Details
Sharing Care within Private Clinics for Patients with Newly Diagnosed mHSPC - David Morris & Benjamin Garmezy
January 29, 2024
Details
Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen
December 15, 2023
Details
Apalutamide plus Androgen Deprivation Therapy in Clinical Subgroups of Patients with Metastatic Castration-Sensitive Prostate Cancer: A Subgroup Analysis of the Randomised Clinical TITAN Study - Beyond the Abstract
December 12, 2023
Details
Chinese Subgroup Analysis Reveals Both Similar and Distinct Responses to Novel Darolutamide Combination Therapy - Yao Zhu
December 11, 2023
Details
ARASENS Phase 3 Clinical Trial Regimen Demonstrates Significant Survival Benefit for Chinese Patients - Yong YANG
December 11, 2023
Details
Combination Therapy Jolts 'Exhausted' Immune Cells Awake to Attack Tumors in Patients with Metastatic Castration-Sensitive Prostate Cancer - Jessica Hawley & Aleksandar Obradovic
November 29, 2023
Details
Harnessing Tumor Biology to Improve Outcomes in Advanced Hormone-Sensitive Prostate Cancer - Gerhardt Attard
November 17, 2023
Details
Deep PSA Response Following Addition of Darolutamide to ADT and Docetaxel in ARASENS - Fred Saad
June 27, 2023
Details
Beyond Medical Advancements: Addressing Financial and Personal Challenges in Metastatic Castration-Sensitive Prostate Cancer Treatment - Neeraj Agarwal
June 14, 2023
Details
The Combination of Enzalutamide Plus Talazoparib for Patients With Castration-Sensitive Metastatic Prostate Cancer With HRR Gene Alterations (TALAPRO-3) - Neeraj Agarwal
March 4, 2023
Details
mHSPC Network Meta-Analysis on the Use of Intensified Treatments - Fred Saad
February 3, 2023
Details
Treatment Intensification in Metastatic Castrate-Sensitive Prostate Cancer - Zachary Klaassen
February 2, 2023
Details
Considerations for Integrating Triplet Therapy Into Clinical Practice - Evan Yu
January 31, 2023
Details
Meta-Analysis Sheds Light on Optimal Treatment Strategies for Metastatic Hormone-Sensitive Prostate Cancer - Benjamin Maughan
January 26, 2023
Details
Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer, Advances and Barriers – Cora Sternberg
January 23, 2023
Details
Progress in Treating Metastatic Castration-Sensitive Prostate Cancer - Karim Fizazi
January 17, 2023
Details
mCSPC Couplet vs Triplet Therapy LUGPA 2022 Presentation - Alicia Morgans
December 15, 2022
Details
Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-risk mHSPC, CYCLONE 3 - Rana McKay
December 5, 2022
Details
The Intensified Treatment Landscape of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Russell Szmulewitz
November 16, 2022
Details
8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam
November 11, 2022
Details
The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore
October 17, 2022
Details
APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu
October 16, 2022
Details
(AFT19) PRESTO Study Prolonging Biochemical Progression-Free Survival in Biochemically Relapsed Prostate Cancer with Intensification of ADT - Charles Ryan
October 12, 2022
Details
Prolonging PSA Progression-Free Survival with Intensification of ADT, the PRESTO Study (AFT19) - Rahul Aggarwal
October 12, 2022
Details
From ADT to Triplet Therapy: Rethinking Treatment Paradigms in Metastatic Hormone Sensitive Prostate Cancer - Matthew Smith & Kim Chi
September 27, 2022
Details
Treatment of Vulnerable/Frail Patients with mHSPC APCCC 2022 Presentation - Alicia Morgans
September 21, 2022
Details
Optimal Treatment for mHSPC from a Health Economics Standpoint APCCC 2022 Presentation - Caroline Clarke
September 21, 2022
Details
Can Biology Help Inform Treatment Decisions In the Management of mHSPC? APCCC 2022 Presentation - Gert Attard
September 11, 2022
Details
Advancing Treatment for Metastatic Hormone-Sensitive Prostate Cancer: Insights from ARASENS Trial - Jan Philipp Radtke
August 31, 2022
Details
Treatment De-escalation Strategies in mHSPC APCCC 2022 Presentation - Bertrand Tombal
August 23, 2022
Details
Treatment Intensification Strategies in mHSPC: Triplets and More APCCC 2022 Presentation - Christopher Sweeney
August 23, 2022
Details
When Low-Volume on Conventional Imaging Goes Into High-Volume on Next-Generation Imaging in mHSPC - Treat like Low-Volume APCCC 2022 Presentation - Karim Fizazi
August 22, 2022
Details
When Low-Volume on Conventional Imaging Goes into High-Volume on Next-Generation Imaging in mHSPC - How Frequent Is This Situation? APCCC 2022 Presentation - Michael Hofman
August 22, 2022
Details
The Uptake of New Treatment Options for mHSPC in Real Life -- Education, Access, Use, and Diversity APCCC 2022 Presentation - Andrew Armstrong
August 22, 2022
Details
A Urologist's Perspective On Treatment with Darolutamide in the Metastatic Hormone Sensitive Patient - Neal Shore
August 8, 2022
Details
Outcomes of the ARASENS Trial by Metastatic Subtype - Bertrand Tombal
August 8, 2022
Details
Darolutamide Approved for Patients with mHSPC - Charles Ryan
August 5, 2022
Details
De-escalation Treatment Strategies in Metastatic Hormone-Sensitive Prostate Cancer - Bertrand Tombal
June 24, 2022
Details
When Low-Volume on Conventional Imaging Goes Into High-Volume on Next-Generation Imaging in mHSPC - Karim Fizazi
June 19, 2022
Details
The Importance of Multidisciplinary Collaboration in Urology Clinics - Neal Shore
June 8, 2022
Details
Real-World Treatment Trends in Metastatic Castration-Sensitive Prostate Cancer - Pedro Barata
March 25, 2022
Details
Practice Changing Data from ARASENS - Statistically Significant Overall Survival - Fred Saad, Bertrand Tombal, and Neal Shore
March 23, 2022
Details
ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Journal Club - Christopher Wallis & Zachary Klaassen
March 21, 2022
Details
Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi
February 24, 2022
Details
Trials and Tribulations in the Management of Metastatic Hormone-Sensitive Prostate Cancer - Heather Payne
December 2, 2021
Details
The Efficacy of Enzalutamide + ADT vs Placebo + ADT in Patients Who Received Prior Antiandrogen Therapy in the ARCHES Study – Neal Shore
September 27, 2021
Details
Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi
September 19, 2021
Details
Radiographic Progression Free Survival in Metastatic Hormone Sensitive Prostate Cancer, The ARCHES Study - Daniel Petrylak
July 18, 2021
Details
The Upfront PSMA Study: Shifting Paradigms in Metastatic Hormone-Sensitive Disease - Declan Murphy & Arun Azad
July 1, 2021
Details
Intensification of Hormonal Therapy for Men With Metachronous Metastatic Hormone-Sensitive Disease – Chris Sweeney
June 21, 2021
Details
Selection of Androgen Deprivation Therapy for Use in Advanced Prostate Cancer - Bertrand Tombal
May 13, 2021
Details
Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study - Neeraj Agarwal
April 30, 2021
Details
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer - Matthew Deek & Phuoc Tran
February 14, 2021
Details
Standard of Care in the Treatment of Metastatic Hormone-Sensitive Prostate Cancer - Michael Morris & Christopher Sweeney
September 13, 2020
Details
Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Evan Yu
June 26, 2020
Details
Quality of Life in the Treatment of mHSPC: The STAMPEDE Trial - Hannah Rush
March 3, 2020
Details
Categorizing Patients with Hormone-Sensitive Prostate Cancer - Christopher Sweeney
February 2, 2020
Details
Systemic Therapies in High Volume & Low Volume Disease in the Treatment of Metastatic Hormone Sensitive Prostate Cancer from the STAMPEDE Trial- Nick James
January 1, 2020
Details
The Biology of Prostate Cancer - Kenneth Pienta
November 26, 2019
Details
Prolonging Time to Metastatic Disease, The SPARTAN Study - Matthew Smith
October 29, 2019
Details
Patient-reported Outcomes from TITAN: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer - Neeraj Agarwal
October 22, 2019
Details
Treating the Primary in High vs Low Volume Hormone Sensitive Disease - Interview Noel Clarke
October 4, 2019
Details
First - Line mCRPC After ADT + Docetaxel or AR Pathway Inhibitor Presentation - Mary-Ellen Taplin
September 24, 2019
Details
Optimal Glucocorticoid Regimen with Abiraterone Acetate Presentation - Gert Attard
September 16, 2019
Details
Follow Up of ADT Alone vs. ADT "Plus" Presentation - William Oh
September 10, 2019
Details
Addition of AR Pathway Inhibitors vs. Docetaxel: Statisticians' Perspective Presentation - Matthew R Sydes
September 10, 2019
Details
The Upheaval in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Chris Sweeney & Mary-Ellen Taplin
August 19, 2019
Details
TITAN, TALAPRO-2 And Ongoing Clinical Trials for Prostate Cancer - Neeraj Agarwal
August 18, 2019
Details
Clinical Implications of TITAN in mHSPC - Kim Chi and Michael Morris
June 22, 2019
Details
Combinatorial Treatment Strategies in mHSPC - Mary-Ellen Taplin
June 5, 2019
Details
Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans
May 26, 2019
Details
Contemporary Management of Hormone Sensitive Prostate Cancer - Alicia Morgans
April 9, 2019
Details
Patients' Quality of Life in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treatment Decisions - Alicia Morgans
June 16, 2019
Details
The Role of the Nurse Practitioner in the Treatment of mHSPC - Leanne Schimke
March 26, 2019
Details
Treatment Decision Making for the Metastatic Hormone-Sensitive Prostate Cancer Patient Population - Alicia Morgans
January 31, 2019
Details
STAMPEDE Trial Updates in Prostate Cancer - Silke Gillessen
December 5, 2018
Details
A Review on Practice Informing Prostate Cancer Study Results - Christopher Sweeney
November 29, 2018
Details
Radical Prostatectomy for Patients with Oligometastatic Prostate Cancer - Robert Hamilton
March 5, 2018
Details